Search
CELL BANK Website

Back Back
RCB1005 : KP4  update : 2018/07/06
CommentPancreatic ductal cell carcinoma. Mother cell line of KP4-1, -2, and -3.
Comment from the depositor
Terms and conditionsBasically, there is no restriction regarding academic use.
Remarks
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Nishi, Y. & Nawata, H.
Originator Nawata, H. & Nishi, Y.
Year of deposit 1994
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 50 years
Tissue pancreas, ascites meta
Case history pancreatic ductal cell carcino
Metastastatic ability Yes
Metastatsd tissue liver, lung, etc
Classification cancer
Year of origin 1990
History Direct from originator.
Memo_1 Mycoplasma was eliminated with MC-210 by the depositor.
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM/HamF12 + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 1-2 times/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR (human) OK
Isozyme LD, NP
Chromosome mode 62-174(50) : /64(6),65(6),67(8),69(6),70(5),71(2)/
Images
deposit info
lot info
Reference information Reference 1
User's Publication 17


To topTop
Reference
1840  Establishment and characterization of PTHrP-producing human pancreatic cancer cell line  Nishi, Y., Haji, M., Takayanagi, R., Iguchi, H., Shimazoe, T., Hirata, J., and Nawata, H.  Int J Oncol  1994  5:33-39  PubMed ID: 21559554

To topTop
User's Publication
3106  Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines.  Takeda, Ami, Osaki, Mitsuhiko, Adachi, Keiko, Honjo, Soichiro, Ito, Hisao  Pancreas  2004  28:353-8  PubMed ID: 15084985
7191  Feasibility of Using an Enzymatically Activatable Fluorescence Probe for the Rapid Evaluation of Pancreatic Tissue Obtained Using Endoscopic Ultrasound-Guided Fine Needle Aspiration: a Pilot Study.  Kawakubo K, Ohnishi S, Hatanaka Y, Hatanaka KC, Hosono H, Kubota Y, Kamiya M, Kuwatani M, Kawakami H, Urano Y, Sakamoto N.  Mol Imaging Biol  2015  18:463-71  PubMed ID: 26431952
7372  Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer.  Miwa T, Kokuryo T, Yokoyama Y, Yamaguchi J, Nagino M.  Cancer Med  2015  4:1091-100  PubMed ID: 25914189
7696  Antitumor effects of α-bisabolol against pancreatic cancer.  Seki T, Kokuryo T, Yokoyama Y, Suzuki H, Itatsu K, Nakagawa A, Mizutani T, Miyake T, Uno M, Yamauchi K, Nagino M.  Cancer Sci.  2011  102:2199-205  PubMed ID: 21883695
8748  MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.  Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M.  Cancer Res.  2008  68:4360-8  PubMed ID: 18519697
9663  Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown.  Tarhan YE, Kato T, Jang M, Haga Y, Ueda K, Nakamura Y, Park JH.  Neoplasia  2016  18:265-272  PubMed ID: 27237318
9977  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.  Sellmann C, Doerner A, Knuehl C, Rasche N, Sood V, Krah S, Rhiel L, Messemer A, Wesolowski J, Schuette M, Becker S, Toleikis L, Kolmar H, Hock B.  J. Biol. Chem.  2016  291:25106-25119  PubMed ID: 27694443
10049  AMPD3 is associated with the malignant characteristics of gastrointestinal stromal tumors.  Wong M, Funasaka K, Obayashi T, Miyahara R, Hirooka Y, Hamaguchi M, Goto H, Senga T.  Oncol Lett  2017  13:1281-1287  PubMed ID: 28454247
10120  The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer.  Murata Y, Kokuryo T, Yokoyama Y, Yamaguchi J, Miwa T, Shibuya M, Yamamoto Y, Nagino M.  Anticancer Res.  2017  37:589-598  PubMed ID: 28179305
10220  Verapamil treatment induces cytoprotective autophagy by modulating cellular metabolism.  Kania E, Pająk B, O'Prey J, Sierra Gonzalez P, Litwiniuk A, Urbańska K, Ryan KM, Orzechowski A.  FEBS J.  2017  284:1370-1387  PubMed ID: 28342290
11016  Population Pharmacokinetics of Liposomal Irinotecan    CLINICAL PHARMACOLOGY & THERAPEUTICS  2017  102  PubMed ID: 28445610
5018  Frizzled-2: A potential novel target for molecular pancreatic cancer therapy.  Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T.  Oncol Lett  2014  7(1):74-78  PubMed ID: 24348824
5022  Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.  Mitsuno M, Kitajima Y, Ohtaka K, Kai K, Hashiguchi K, Nakamura J, Hiraki M, Noshiro H, Miyazaki K.  Int J Oncol  2010  36(2):341-9  PubMed ID: 20043067
5843  EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.  Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A.  Clin Cancer Res  2013  19(11):2941-51  PubMed ID: 23553846
5875  Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.  Mishra R, Miyamoto M, Yoshioka T, Ishikawa K, Matsumura Y, Shoji Y, Ichinokawa K, Itoh T, Shichinohe T, Hirano S, Kondo S.  Int J Oncol  2009  34(5):1231-40  PubMed ID: 19360336
11811  Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer.  Mohammad GH, Vassileva V, Acedo P, Olde Damink SWM, Malago M, Dhar DK, Pereira SP.  Cancers (Basel)  2019    PubMed ID: 31527446
11831  Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.  Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS, Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman J, Hahn WC, Aguirre AJ.  Cell Rep  2019    PubMed ID: 31577942



Back Back Return Top Page